A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Advanced Gastrointestinal Cancer Clinical Trial

Official title:

A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02024607
• Other study ID #: BBI608-246
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 2014
• Est. completion date: November 2019

Study information

• Verified date: November 2023
• Source: Sumitomo Pharma America, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan.

Description:

This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan. A study cycle will consist of daily and continuous oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 495
• Est. completion date: November 2019
• Est. primary completion date: March 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent

2. A histologically confirmed solid tumor of the gastrointestinal tract including

1. Advanced unresectable, metastatic or recurrent colorectal carcinoma (CRC) for which treatment with FOLFOX6 with or without bevacizumab, FOLFIRI with or without bevacizumab, CAPOX, or regorafenib would be acceptable as determined by the Investigator. FOLFIRI/XELIRI-refractory patients with CRC enrolling on the FOLFIRI study arm must have failed treatment with one FOLFIRI pr XELIRI with or without bevacizumab regimen for unresectable or metastatic disease. Treatment failure is defined as progression of disease (clinical or radiologic) during treatment with FOLFIRI with or without bevacizumab or < 3 months after the last dose of treatment with FOLFIRI with or without bevacizumab. Patients with CRC enrolling on the regorafenib arm of this study will have previously received at least two previous lines of therapy for advanced colorectal cancer, and will have previously received treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients with K-ras wild type tumors enrolling on the regorafenib arm will also have previously received either cetuximab or panitumumab.

2. Hepatocellular carcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable as determined by the Investigator.

3. Pancreatic adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.

4. Cholangiocarcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable as determined by the Investigator.

5. Gastric, GEJ or esophageal adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.

3. Patients may be treatment naïve, or may have received standard chemotherapy; including regimens containing a fluoropyrimidine, or oxaliplatin, or irinotecan, or regorafenib, or bevacizumab.

4. =18 years of age.

5. Karnofsky performance status score =70%.

6. Male or female patients of child-producing potential agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI608 dose.

7. Females of childbearing potential have a negative serum pregnancy test.

8. AST level =2.5 x ULN and ALT = 2.5 × ULN. For patients with liver metastases, AST =3.5 x ULN, and AST =3.5 x ULN may be enrolled if agreed upon by the investigator and medical monitor for the sponsor.

9. Hemoglobin =10 g/dl.

10. Total bilirubin level =1.5 × ULN.

11. Creatinine =1.5 x ULN or creatinine clearance >60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal (as determined by Cockcroft-Gault equation).

12. Absolute neutrophil count = 1.5 x 10^9/L.

13. Platelets =100 x 10^9/L.

14. Life expectancy estimated at =3 months.

Exclusion Criteria:

1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 7 days of the first dose of BBI608.

2. Major surgery within 4 weeks prior to first dose.

3. Any known untreated brain metastases. Treated subjects must be stable for 4 weeks after completion of that treatment, with image documentation required. Patients must have no clinical symptoms from brain metastases and must be either off steroids or on a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients with known leptomeningeal metastases are excluded, even if treated.

4. Pregnant or breastfeeding.

5. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent

6. Unable or unwilling to swallow BBI608 capsules daily.

7. Prior treatment with BBI608.

8. Uncontrolled intercurrent illness

9. For patients to be treated with a regimen containing 5-fluorouracil/leucovorin:

1. Known hypersensitivity to 5-fluorouracil/leucovorin

2. Known dihydropyrimidine dehydrogenase (DPD) deficiency

10. For patients to be treated with a regimen containing capecitabine:

1. Known hypersensitivity to capecitabine

2. Known dihydropyrimidine dehydrogenase (DPD) deficiency

3. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent

11. For patients to be treated with a regimen containing oxaliplatin:

1. Neurosensory neuropathy = grade 2 at baseline

2. Known hypersensitivity to oxaliplatin or other platinum containing compounds

12. For patients to be treated with a regimen containing irinotecan:

1. Known hypersensitivity to irinotecan

2. Abnormal glucuronidation of bilirubin

13. For patients to be treated with a regimen containing bevacizumab:

1. Current uncontrolled hypertension as well as prior history of hypertensive crisis or hypertensive encephalopathy

2. History of cardiac disease: congestive heart failure (CHF) > NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy

3. History of arterial thrombotic or embolic events (within 6 months prior to study entry)

4. Significant vascular disease

5. Evidence of bleeding diathesis or clinically significant coagulopathy

6. Major surgical procedure within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure within 7 days prior to study enrollment

7. Proteinuria at screening as demonstrated by urinalysis with proteinuria = 2+.

8. History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra-abdominal abscess within 6 months

9. Ongoing serious, non-healing wound, ulcer, or bone fracture

10. Known hypersensitivity to any component of bevacizumab

11. History of reversible posterior leukoencephalopathy syndrome (RPLS)

14. For patients to be treated with a regimen containing regorafenib:

1. History of cardiac disease: congestive heart failure (CHF) > NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy

2. Current uncontrolled hypertension

3. Interstitial lung disease with ongoing signs and symptoms at the time of screening

4. History of HIV infection or chronic hepatitis B or C

5. Active clinically serious infections

6. History of arterial or embolic events (within 6 months prior to study entry)

7. Liver cirrhosis = Child-Pugh class B with uncontrolled ascites

8. History of RPLS

9. Ongoing serious, non-healing wound, ulcer, or bone fracture

10. Evidence of bleeding diathesis or a clinically significant coagulopathy

11. Renal failure requiring hemo- or peritoneal dialysis

12. Persistent proteinuria of CTCAE grade 3 (>3.5g/24 hours)

13. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent

14. Known hypersensitivity to regorafenib

Related Conditions & MeSH terms

• Advanced Gastrointestinal Cancer
• Gastrointestinal Neoplasms

Intervention

Drug:
• BBI608

• Fluorouracil

• Oxaliplatin

• Leucovorin

• Irinotecan

• Bevacizumab

• Capecitabine

• Regorafenib

Locations

Country	Name	City	State
Canada	Ottawa Hospital Cancer Center	Ottawa	Ontario
United States	Emory University Winship Cancer Institute	Atlanta	Georgia
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Tennessee Oncology - Chattanooga	Chattanooga	Tennessee
United States	Oncology Hematology Care, Inc.	Cincinnati	Ohio
United States	Florida Cancer Specialists	Fort Myers	Florida
United States	Parkview Research Center	Fort Wayne	Indiana
United States	Indiana University Health Goshen Center for Cancer Care	Goshen	Indiana
United States	Institute for Translational Oncology Research, Greenville Health System	Greenville	South Carolina
United States	Indiana University Simon Cancer Center	Indianapolis	Indiana
United States	Indiana University Health Arnett Hospital	Lafayette	Indiana
United States	Indiana University Health Ball Memorial Hospital	Muncie	Indiana
United States	Tennessee Oncology - Nashville	Nashville	Tennessee
United States	Mayo Clinic Campus in Arizona	Phoenix	Arizona
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Sumitomo Pharma America, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events and Serious Adverse Events	Assessment of safety of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan in participants with advanced gastrointestinal malignancies by reporting of adverse events and serious adverse events	The time from the date of first treatment, while the patient is taking napabucasin, and for 30 days after stopping therapy, an average of 4 months.
Primary	The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer	Assessment of the objective response rate (ORR) of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. The Objective Response Rate (ORR) is the proportion of participants with a complete response or partial response who have measurable disease at baseline imaging.	From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months
Secondary	Determination of the Maximum Observed Concentration (Cmax) and Area Under the Plasma Concentration vs. Time Curve (AUClast)	To determine the maximum concentration of napabucasin and the area under the plasma concentration vs. time curve of napabucasin when administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib.	Blood samples drawn on days 1, 2, 15, 16, 21, and 22 of the first study cycle
Secondary	Pharmacodynamics	To determine the response (increase or decrease) of biomarkers from biopsied tumors following the administration of napabucasin	Day 1 of cycle 2
Secondary	Disease Control Rate	To determine the anti-tumor activity (specifically the disease control rate) of napabucasin administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1.	From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months.
Secondary	Disease Control Rate of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer	To determine the disease control rate of napabucasin administered in combination with FOLFIRI in patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. Percentage of participants with a documented complete response, partial response and stable disease based on RECIST 1.1.	From the date of first treatment, every 8 weeks, until the date of first documented objective disease progression, up to 24 months
Secondary	Progression Free Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer	The effect of napabucasin given in combination with FOLFIRI on Progression Free Survival (PFS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer. PFS of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer.	The time from the date of first treatment to the date of first documentation of disease progression or death due to any cause, up to thirty six months
Secondary	Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer	The effect of napabucasin given in combination with FOLFIRI on Overall Survival (OS) of patients with FOLFIRI/XELIRI-refractory metastatic colorectal cancer.	4 weeks after the patient has been off study treatment, every 3 months thereafter until death, the study closes, up to 36 months.